Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Tricida, Inc. (TCDA)

0.108   0 (0%) 01-23 16:00
Open: 0.1156 Pre. Close: 0.108
High: 0.116 Low: 0.0925
Volume: 31,125,310 Market Cap: 6(M)

Technical analysis

as of: 2023-01-27 4:48:26 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.22     One year: 0.3
Support: Support1: 0.09    Support2: 0.07
Resistance: Resistance1: 0.19    Resistance2: 0.25
Pivot: 0.15
Moving Average: MA(5): 0.12     MA(20): 0.15
MA(100): 4.35     MA(250): 7.62
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 4.4     %D(3): 3.5
RSI: RSI(14): 24.4
52-week: High: 13.85  Low: 0.09
Average Vol(K): 3-Month: 13,987 (K)  10-Days: 22,690 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TCDA ] has closed above bottom band by 0.5%. Bollinger Bands are 97.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 47 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.12 - 0.12 0.12 - 0.12
Low: 0.09 - 0.09 0.09 - 0.09
Close: 0.11 - 0.11 0.11 - 0.11

Company Description

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Headline News

Fri, 27 Jan 2023
Team Creates New Method to Detect C Difficile in Fecal Samples - MD Magazine

Mon, 23 Jan 2023
Where Will Tricida Inc (TCDA) Stock Go Next After It Is Lower By 33.33% in a Week? - InvestorsObserver

Wed, 18 Jan 2023
Tricida Inc (TCDA) Stock: Do Analysts Think You Should Hold? - InvestorsObserver

Wed, 18 Jan 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace

Tue, 17 Jan 2023
Stocks Mostly Lower Tuesday as Investors Digest Mixed Earnings - InvestorsObserver

Fri, 13 Jan 2023
5 Cheapest Health Care Stocks You Should Think About - Benzinga

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 58 (M)
Shares Float 51 (M)
% Held by Insiders 8 (%)
% Held by Institutions 64.7 (%)
Shares Short 10,820 (K)
Shares Short P.Month 14,640 (K)

Stock Financials

EPS -2.88
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.45
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -60.2
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.14
Qtrly Earnings Growth 0
Operating Cash Flow -109 (M)
Levered Free Cash Flow -66 (M)

Stock Valuations

PE Ratio -0.04
PEG Ratio 0
Price to Book value -0.05
Price to Sales 0
Price to Cash Flow -0.06

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.